Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Fifty 1 Labs, Inc. (OTC: FITY), a pioneer in AI-powered health and wellness solutions, in collaboration with UAV Corp (OTC: UMAV), is set to host a virtual shareholder teleconference on July 28, 2025, at 12:00 PM EST. The event will be streamed live on X (formerly Twitter) and will feature Dr. James Orbinski, a Senior Scientist and Nobel Peace Prize laureate, who accepted the award on behalf of Médecins Sans Frontières (Doctors Without Borders) in 1999. This teleconference aims to shed light on Fifty 1 Labs' strategic direction for its subsidiary, Fifty 1 AI Labs, including advancements in AI-driven drug repurposing for functional medicine, a significant $1 million R&D investment, and ambitious plans for a $5–10 million biotech acquisition by 2027.

The company's leadership has demonstrated a strong commitment to shareholder alignment, evidenced by $350,000 in personal investments and the decision to defer salaries until achieving a $50 million valuation or within a two-year timeframe. CEO Paul Arora emphasized the company's strategic focus on off-patent drug repurposing and adaptive trials, which positions Fifty 1 Labs for substantial growth and a meaningful impact on global health. This initiative underscores the company's dedication to leveraging cutting-edge technology and scientific expertise to address pressing health challenges.

Fifty 1 Labs, Inc. operates as a holding company with a keen focus on innovation within the health, wellness, and biotechnology sectors. It fully owns Genetic Networks LLC, a biotech firm renowned for its GeneScape platform, a yeast-based, whole-genome analysis tool that expedites drug discovery for personalized medicine, biodefense, and wellness applications. The company also wholly owns 51, LLC, its sports nutrition subsidiary, which offers a premium line of supplements designed to enhance athletic performance, recovery, and overall health. This teleconference represents a pivotal moment for Fifty 1 Labs as it seeks to articulate its vision and strategic priorities to shareholders and the broader investment community.